Veru plans Phase 2 trial for oral sabizabulin
Veru says it is advancing oral sabizabulin after positive preclinical data into a planned Phase 2 clinical trial.
Story updates
12:23:47 PM UTC
SquawkNews
Veru advances sabizabulin into a planned Phase 2 trial after preclinical data show potent activity (IC50=18.2 nM) in daraxonrasib—resistant KRAS pancreatic cancer.Key Highlights:Original SEC Filing: VERU INC. [ VERU ] - 8-K - Sep. 08, 2026This is an AI-powered summary. It may contain inaccuracies…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.